S
MSCL
vs
S
S&P TSX Composite Index (Canada)
Over the past 12 months, MSCL has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +34% growth.
Stocks Performance
MSCL vs S&P TSX Composite Index (Canada)
Performance Gap
MSCL vs S&P TSX Composite Index (Canada)
Performance By Year
MSCL vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Satellos Bioscience Inc
Glance View
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. The company is headquartered in Toronto, Ontario. The company went IPO on 2006-12-01. The firm is engaged in developing therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct dysregulated muscle stem-cell polarity, which balances replenishment of muscle stem cells and production of specialized tissue cells. The company uses MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders. The company also maintains two clinical stage products: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. iCo-008 provides treatment of the dermatological condition bullous pemphigoid (BP), atopic dermatitis, gastrointestinal conditions, and age-related macular degeneration (AMD). Oral Amphotericin B delivery system provides treatment of Visceral Leishmaniasis (VL).
